Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | LEGN |
---|---|---|
09:32 ET | 1797 | 44.76 |
09:38 ET | 200 | 44.615 |
09:39 ET | 100 | 44.5 |
09:41 ET | 746 | 44.48 |
09:43 ET | 100 | 44.36 |
09:45 ET | 1163 | 44.34 |
09:48 ET | 400 | 44.2 |
09:50 ET | 200 | 44.2 |
09:52 ET | 100 | 44.2 |
09:54 ET | 200 | 44.06 |
09:56 ET | 300 | 44.02 |
09:57 ET | 500 | 44.02 |
09:59 ET | 2174 | 43.83 |
10:01 ET | 4079 | 43.74 |
10:03 ET | 2333 | 43.835 |
10:06 ET | 2115 | 43.875 |
10:08 ET | 275 | 43.87 |
10:10 ET | 200 | 43.835 |
10:12 ET | 1200 | 43.83 |
10:14 ET | 1400 | 43.725 |
10:15 ET | 5792 | 44.01 |
10:17 ET | 5080 | 44.41 |
10:19 ET | 1240 | 44.51 |
10:21 ET | 935 | 44.34 |
10:24 ET | 1908 | 44.34 |
10:26 ET | 3519 | 44.3 |
10:28 ET | 2910 | 44.195 |
10:30 ET | 600 | 44.13 |
10:32 ET | 400 | 44.16 |
10:33 ET | 1100 | 44.16 |
10:35 ET | 2269 | 44.165 |
10:37 ET | 1432 | 44.225 |
10:39 ET | 1242 | 44.12 |
10:42 ET | 2625 | 44.195 |
10:44 ET | 2537 | 44.275 |
10:46 ET | 2120 | 44.335 |
10:48 ET | 1316 | 44.33 |
10:50 ET | 2948 | 44.26 |
10:51 ET | 825 | 44.23 |
10:53 ET | 1149 | 44.15 |
10:55 ET | 400 | 44.175 |
10:57 ET | 2706 | 44.275 |
11:00 ET | 1638 | 44.36 |
11:02 ET | 767 | 44.41 |
11:04 ET | 300 | 44.37 |
11:06 ET | 1397 | 44.34 |
11:08 ET | 1300 | 44.37 |
11:09 ET | 300 | 44.45 |
11:11 ET | 500 | 44.35 |
11:13 ET | 500 | 44.34 |
11:15 ET | 2197 | 44.285 |
11:18 ET | 300 | 44.25 |
11:20 ET | 1000 | 44.23 |
11:22 ET | 200 | 44.26 |
11:24 ET | 400 | 44.23 |
11:26 ET | 100 | 44.24 |
11:27 ET | 458 | 44.24 |
11:29 ET | 1653 | 44.33 |
11:31 ET | 1100 | 44.36 |
11:33 ET | 1332 | 44.42 |
11:36 ET | 1077 | 44.47 |
11:38 ET | 1100 | 44.46 |
11:40 ET | 3791 | 44.375 |
11:42 ET | 100 | 44.38 |
11:44 ET | 6602 | 44.51 |
11:45 ET | 1930 | 44.53 |
11:47 ET | 1039 | 44.555 |
11:49 ET | 951 | 44.56 |
11:51 ET | 613 | 44.61 |
11:54 ET | 2465 | 44.68 |
11:56 ET | 3006 | 44.685 |
11:58 ET | 2399 | 44.73 |
12:00 ET | 3251 | 44.71 |
12:02 ET | 3556 | 44.715 |
12:03 ET | 500 | 44.7 |
12:05 ET | 200 | 44.695 |
12:07 ET | 407 | 44.705 |
12:09 ET | 6071 | 44.69 |
12:12 ET | 5772 | 44.54 |
12:16 ET | 200 | 44.54 |
12:18 ET | 777 | 44.515 |
12:20 ET | 792 | 44.4 |
12:21 ET | 1303 | 44.47 |
12:23 ET | 1359 | 44.56 |
12:25 ET | 750 | 44.55 |
12:27 ET | 342 | 44.53 |
12:30 ET | 400 | 44.55 |
12:32 ET | 400 | 44.625 |
12:34 ET | 403 | 44.635 |
12:36 ET | 1134 | 44.625 |
12:38 ET | 1200 | 44.68 |
12:39 ET | 1067 | 44.56 |
12:41 ET | 300 | 44.535 |
12:43 ET | 447 | 44.6 |
12:48 ET | 400 | 44.59 |
12:50 ET | 264 | 44.59 |
12:52 ET | 2468 | 44.67 |
12:54 ET | 1626 | 44.68 |
12:56 ET | 100 | 44.645 |
12:57 ET | 100 | 44.64 |
12:59 ET | 1199 | 44.65 |
01:01 ET | 800 | 44.64 |
01:03 ET | 500 | 44.64 |
01:06 ET | 720 | 44.57 |
01:08 ET | 976 | 44.38 |
01:10 ET | 1200 | 44.46 |
01:12 ET | 300 | 44.51 |
01:15 ET | 2014 | 44.6 |
01:17 ET | 100 | 44.61 |
01:19 ET | 500 | 44.64 |
01:21 ET | 1920 | 44.62 |
01:24 ET | 502 | 44.63 |
01:26 ET | 600 | 44.62 |
01:28 ET | 2325 | 44.6 |
01:30 ET | 300 | 44.49 |
01:32 ET | 900 | 44.4875 |
01:33 ET | 785 | 44.4 |
01:35 ET | 1147 | 44.38 |
01:37 ET | 1104 | 44.43 |
01:39 ET | 700 | 44.46 |
01:42 ET | 754 | 44.4 |
01:44 ET | 200 | 44.425 |
01:46 ET | 1542 | 44.4 |
01:48 ET | 737 | 44.42 |
01:50 ET | 947 | 44.45 |
01:51 ET | 600 | 44.47 |
01:53 ET | 1000 | 44.49 |
01:55 ET | 1200 | 44.51 |
01:57 ET | 200 | 44.48 |
02:00 ET | 1000 | 44.45 |
02:02 ET | 400 | 44.43 |
02:04 ET | 1022 | 44.42 |
02:06 ET | 400 | 44.45 |
02:08 ET | 500 | 44.425 |
02:09 ET | 2714 | 44.43 |
02:11 ET | 300 | 44.41 |
02:13 ET | 792 | 44.46 |
02:15 ET | 1537 | 44.46 |
02:18 ET | 100 | 44.46 |
02:20 ET | 461 | 44.42 |
02:22 ET | 100 | 44.415 |
02:24 ET | 1700 | 44.34 |
02:26 ET | 1388 | 44.4 |
02:27 ET | 1052 | 44.48 |
02:29 ET | 565 | 44.52 |
02:31 ET | 100 | 44.48 |
02:33 ET | 962 | 44.43 |
02:38 ET | 800 | 44.42 |
02:40 ET | 400 | 44.44 |
02:42 ET | 1352 | 44.44 |
02:44 ET | 1000 | 44.375 |
02:45 ET | 200 | 44.38 |
02:47 ET | 200 | 44.34 |
02:49 ET | 3077 | 44.2 |
02:51 ET | 928 | 44.21 |
02:54 ET | 1000 | 44.23 |
02:56 ET | 1100 | 44.26 |
02:58 ET | 1015 | 44.265 |
03:00 ET | 2394 | 44.24 |
03:02 ET | 2000 | 44.195 |
03:03 ET | 3417 | 44.215 |
03:05 ET | 1195 | 44.15 |
03:07 ET | 300 | 44.14 |
03:09 ET | 2740 | 44.19 |
03:12 ET | 1267 | 44.1525 |
03:14 ET | 800 | 44.18 |
03:16 ET | 1416 | 44.15 |
03:18 ET | 878 | 44.08 |
03:20 ET | 956 | 44.04 |
03:21 ET | 1763 | 44.06 |
03:23 ET | 2600 | 44.075 |
03:25 ET | 1656 | 43.96 |
03:27 ET | 756 | 43.96 |
03:30 ET | 4740 | 43.89 |
03:32 ET | 4332 | 43.93 |
03:34 ET | 1000 | 43.93 |
03:36 ET | 3226 | 43.95 |
03:38 ET | 1115 | 43.93 |
03:39 ET | 400 | 43.92 |
03:41 ET | 1066 | 43.885 |
03:43 ET | 4600 | 43.93 |
03:45 ET | 1696 | 43.9 |
03:48 ET | 2102 | 43.88 |
03:50 ET | 3236 | 43.88 |
03:52 ET | 5503 | 44.11 |
03:54 ET | 4681 | 44.13 |
03:56 ET | 9558 | 44.37 |
03:57 ET | 9614 | 44.35 |
03:59 ET | 114984 | 44.29 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Legend Biotech Corp | 8.1B | -17.0x | --- |
Ascendis Pharma A/S | 7.9B | -14.3x | --- |
Blueprint Medicines Corp | 6.7B | -22.4x | --- |
Intra-Cellular Therapies Inc | 7.2B | -59.4x | --- |
Vaxcyte Inc | 8.2B | -17.9x | --- |
Cerevel Therapeutics Holdings Inc | 7.4B | -15.0x | --- |
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $8.1B |
---|---|
Revenue (TTM) | $342.8M |
Shares Outstanding | 182.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.11 |
EPS | $-2.60 |
Book Value | $6.88 |
P/E Ratio | -17.0x |
Price/Sales (TTM) | 23.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -157.97% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.